N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios ...

Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

On Monday, Prime Medicine Inc (PRME) stock saw a modest uptick, ending the day at $3.87 which represents a slight increase of $0.41 or 11.85% from the prior close of $3.46. The stock opened at $4.23 ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Prime Medicine, founded with gene-editing tech from the lab of star Harvard biochemist David Liu and backed by blue chip investors, made little secret of its ambition. It laid out plans to use ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

Next-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company update and news of ...

Arguably the more significant of the two pieces of news was that partnership deal. Prime Medicine announced that it had signed a strategic research collaboration and license agreement with global ...